eIF-4A: A Protein Target for Cancer and Neurodegenerative Diseases
eIF-4A: A Protein Target for Cancer and Neurodegenerative Diseases
Eukaryotic Translation Initiation Factor 4A (eIF-4A) is a protein that plays a crucial role in the process of translation of RNA into proteins in eukaryotic cells. Mutations in eIF-4A have been linked to a variety of diseases, including cancer, neurodegenerative diseases , and developmental disorders. As a result, eIF-4A has become a promising drug target and a focus of research in the field of biotechnology.
The eIF-4A protein is a key component of the eIF4F complex, which is responsible for initiating the process of translation of RNA into protein. The eIF4F complex consists of the protein eIF-4A, eIF-4B, 鈥嬧?媏IF-5A, and eIF- 5B. The role of eIF-4A is to bind to the mRNA and facilitate the recruitment of eIF-4B and eIF-5B to the nuclear kernel, where they interact with the small nuclear RNA (snRNA) pool. This interaction between eIF-4A , eIF-4B, 鈥嬧?媋nd eIF-5B are critical for the initiation of translation.
Recent studies have shown that eIF-4A plays a crucial role in the regulation of protein translation in eukaryotic cells. Mutations in eIF-4A have been linked to a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, studies have shown that eIF-4A mutations are associated with increased translation of tumor-promoting genes in cancer cells. Additionally, eIF-4A mutations have been linked to neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.
As a result, eIF-4A has become a promising drug target and a focus of research in the field of biotechnology. Researchers are exploring the use of small molecules, such as drugs, to inhibit the activity of eIF-4A and prevent its dysfunction in diseases. One approach is to use small molecules to bind to specific regions of eIF-4A and prevent its interaction with eIF-4B and eIF-5B. This approach has the potential to be a highly effective and targeted treatment for a variety of diseases.
Another approach is to use antibodies to target eIF-4A directly and prevent its interaction with eIF-4B and eIF-5B. This approach has the potential to be a highly effective and targeted treatment for diseases where eIF-4A dysfunction is known to play a role.
In conclusion, eIF-4A is a protein that plays a crucial role in the process of translation of RNA into proteins in eukaryotic cells. Its dysfunction has been linked to a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. As a result, eIF-4A has become a promising drug target and a focus of research in the field of biotechnology. The use of small molecules and antibodies to inhibit the activity of eIF-4A has the potential to be a highly effective and targeted treatment for a variety of diseases. Further research is needed to fully understand the role of eIF-4A in disease and to develop effective treatments.
Protein Name: Eukaryotic Translation Initiation Factor 4A (eIF-4A)
The "Eukaryotic Translation Initiation Factor 4A (eIF-4A) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Eukaryotic Translation Initiation Factor 4A (eIF-4A) comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
Eukaryotic Translation Initiation Factor 4E Binding Protein | EVA1A | EVA1A-AS | EVA1B | EVA1C | EVC | EVC2 | EVI2A | EVI2B | EVI5 | EVI5L | EVL | EVPL | EVPLL | EVX1 | EVX1-AS | EVX2 | EWSAT1 | EWSR1 | EXD1 | EXD2 | EXD3 | EXO1 | EXO5 | EXOC1 | EXOC1L | EXOC2 | EXOC3 | EXOC3-AS1 | EXOC3L1 | EXOC3L2 | EXOC3L4 | EXOC4 | EXOC5 | EXOC5P1 | EXOC6 | EXOC6B | EXOC7 | EXOC8 | Exocyst complex | EXOG | EXOGP1 | Exon junction complex | EXOSC1 | EXOSC10 | EXOSC10-AS1 | EXOSC2 | EXOSC3 | EXOSC4 | EXOSC5 | EXOSC6 | EXOSC7 | EXOSC8 | EXOSC9 | Exosome Complex | EXPH5 | EXT1 | EXT2 | EXTL1 | EXTL2 | EXTL2P1 | EXTL3 | EXTL3-AS1 | EYA1 | EYA2 | EYA3 | EYA4 | EYS | EZH1 | EZH2 | EZHIP | EZR | F10 | F11 | F11-AS1 | F11R | F12 | F13A1 | F13B | F2 | F2R | F2RL1 | F2RL2 | F2RL3 | F3 | F5 | F7 | F8 | F8A1 | F8A2 | F8A3 | F9 | FA2H | FAAH | FAAH2 | FAAHP1 | FAAP100 | FAAP20 | FAAP24 | FABP1
